Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% i...
JP Morgan analyst Anupam Rama maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $15 ...
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0...
RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developi...
UBS analyst Eliana Merle downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral and lowers the price target from $61...
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma...
